E-viri
Recenzirano
Odprti dostop
-
Temiz, Suleyman; Kaya, Serap; Erbag, Gokhan; Aksu, Gorkem; Uygun, Kazım
Journal of oncological science, April 2016, 2016-04-00, 2016-04-01, Letnik: 2, Številka: 1Journal Article
Epidermal growth factor receptor (EGFR) is overexpressed in several solid human tumor types, such as colorectal, breast and lung cancers. There are strong evidences that EGFR inhibitors have an increased risk of dermatological side effects arise during the treatment of these agents. Lapatinib is an EGFR inhibitor approved for the treatment of patients with recurrent HER2-positive advanced or metastatic breast cancer. Herein, we report a 35 year old female patient, who had lung metastasis associated with breast cancer, with the presence of acneiform eruption in her face and metastatic lesions which did not progress for 17 months while she was having the lapatinib treatment for her metastatic lesions. As it is occur in all other EGFR inhibitors, the development of acneiform eruption during the lapatinib treatment might be an indicator of better and longer drug response.
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.